Evidence map›Paper›PMID 40317901›Full record

ArticleArthritis care & research2025

Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis.

Timothy G Brandon, Rui Xiao, Daniel J Lovell, Edward Oberle, Matthew L Stoll, Nancy A Chauvin, Michael L Francavilla, Walter P Maksymowych, Pamela F Weiss

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Timothy G BrandonChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0002-1305-4871
Rui XiaoPerelman School of Medicine, University of Pennsylvania, and Children's Hospital of Philadelphia.
Daniel J LovellCincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio.ORCID 0000-0003-1604-0130
Edward OberleNationwide Children's Hospital and The Ohio State University, Columbus.ORCID 0000-0003-2171-9340
Matthew L StollUniversity of Alabama at Birmingham.ORCID 0000-0002-6225-3690
Nancy A ChauvinThe Imaging Institute, The Cleveland Clinic, Cleveland, Ohio.
Michael L FrancavillaWhiddon College of Medicine, University of South Alabama, Mobile.
Walter P MaksymowychUniversity of Alberta and CARE Arthritis, Edmonton, Alberta, Canada.ORCID 0000-0002-1291-1755
Pamela F WeissPerelman School of Medicine, University of Pennsylvania, and Children's Hospital of Philadelphia.ORCID 0000-0002-9724-0443

Funding

Refining entry criteria and outcome measures for children with axial disease and spondyloarthritis: preparation for clinical trialsR01AR074098 · NIAMS · CHILDREN'S HOSP OF PHILADELPHIA · PI WEISS, PAMELA FITCH · 2019 to 2021
$678k
NIAMS NIH HHS R01 AR074098NIH HHS 1R01AR074098
6 · The paper itself

Abstract

objectiveThe objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework.

methodsThis was a prospective multicenter study of youth with axJSpA. Participants (aged 8-18 years) all initiated tumor necrosis factor inhibitor (TNFi) therapy and completed questionnaires, examinations, and magnetic resonance imaging (MRI) at baseline and 12 weeks. Responsiveness and discrimination were assessed using standardized response mean (SRM) and standardized mean difference (SMD). For highly correlated (r > |0.80|) items within domains, larger SRM and SMD were prioritized, and minimal clinically important improvement was determined for each.

resultsOf the evaluable cohort (N = 57), 68.4% were male, and the median age was 15.3 years; 70.2% of youth treated with TNFi had clinical response (change ≥2 in patient global assessment). Although 58% had continued MRI inflammation, 77% of those patients reported moderate clinical improvement. The final axJSpA core set contained the following: Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference (SRM 0.77, SMD 0.5), the sacroiliac joint inflammation score (SRM 1.02, SMD 0.52), PROMIS mobility (SRM 0.83, SMD 0.75), and patient global well-being (SRM 0.88, SMD not applicable). All overall and composite disease activity measures tested, except the physician global assessment, had high SRM and SMD. Subgroup analysis demonstrated differences by biologic sex and overweight status. Improvement in the MRI inflammation score was greater in male patients. Improvement in the PROMIS pain interference and mobility measures was greater in those with normal body mass index.

conclusionA set of measures was developed for youth with axJSpA.

Indexed as

Antirheumatic AgentsArthritis, JuvenileAxial SpondyloarthritisPatient Reported Outcome MeasuresPragmatic Clinical Trials as TopicTumor Necrosis Factor InhibitorsAdolescentChildFemaleHumansMagnetic Resonance ImagingMaleProspective StudiesTreatment OutcomeAntirheumatic AgentsTumor Necrosis Factor Inhibitors

Identifiers

PMID40317901
PMCPMC12353632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.